Effect of Short-Term Oral Valproic Acid on Vision and Visual Field in Retinitis Pigmentosa

[1]  B. Rosner,et al.  Lack of scientific rationale for use of valproic acid for retinitis pigmentosa , 2010, British Journal of Ophthalmology.

[2]  L. I. van den Born,et al.  The conclusions of Clemson et al concerning valproic acid are premature , 2010, British Journal of Ophthalmology.

[3]  S. Kaushal,et al.  Therapeutic potential of valproic acid for retinitis pigmentosa , 2010, British Journal of Ophthalmology.

[4]  S. Kaushal,et al.  A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. , 2008, Investigative ophthalmology & visual science.

[5]  M. C. Leske,et al.  Measuring visual field progression in the Early Manifest Glaucoma Trial. , 2003, Acta ophthalmologica Scandinavica.

[6]  I. Chowers,et al.  A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. , 2003, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[7]  B. Rosner,et al.  Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. , 2002, Investigative ophthalmology & visual science.

[8]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[9]  A Heijl,et al.  Early Manifest Glaucoma Trial: design and baseline data. , 1999, Ophthalmology.

[10]  J T Holladay,et al.  Proper method for calculating average visual acuity. , 1997, Journal of refractive surgery.

[11]  L N Johnson,et al.  Visual field interpretation with empiric probability maps. , 1989, Archives of ophthalmology.

[12]  Robert W. Massof,et al.  First order dynamics of visual field loss in retinitis pigmentosa , 1990 .